Overview
Glimepiride is a second-generation sulfonylurea oral hypoglycemic agent. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Mechanism of Action
Like other sulfonylureas, glimepiride lowers blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. It binds to the sulfonylurea receptor, leading to the closure of ATP-sensitive potassium channels, depolarization of the cell membrane, and subsequent insulin secretion.

Dosage and Administration
The starting dose is usually 1 to 2 mg once daily, administered with breakfast or the first main meal. The dose may be titrated based on glycemic response, up to a maximum of 8 mg daily.

Side Effects
Hypoglycemia is the most significant side effect. Weight gain is also common. Less frequent adverse effects include dizziness, headache, nausea, and transient visual disturbances at the start of treatment.

Contraindications
It should not be used in patients with type 1 diabetes, diabetic ketoacidosis, or a history of hypersensitivity to glimepiride or other sulfonylureas. Caution is advised in patients with severe renal or hepatic dysfunction.

Pregnancy and Lactation
Glimepiride should be avoided during pregnancy due to the risk of prolonged hypoglycemia in the neonate. It is also not recommended for nursing mothers as it may be excreted in human milk.